IP Library Granted Patent US 12,653,185
Granted Patent B2
US 12,653,185 · App. 16/312,832 · Granted Jun 16, 2026

Microcapsules encapsulating lambda-cyhalothrin

Inventors: Kal Edly (Greensboro, NC); Matthew Robert Cottle (Greensboro, NC)
Assignee: SYNGENTA CROP PROTECTION AG
A01N25/28A01N53/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,653,185
App. No.
16/312,832
Granted
Jun 16, 2026
Kind
B2
Abstract

A composition comprising a microcapsule having a polyurea wall encapsulating a pyrethroid insecticide, wherein the polyurea wall of the microcapsule is made of polyurea polymers derived from a mixture of aromatic polyisocyanate (A) and aromatic diisocyanate (B), the weight ratio of (A) to (B) is 1:1, the polymer (or wall) content of each microcapsule is from 6 to 9% by weight, and the amount of the pyrethroid insecticide is from 15 to 60% by weight, each based on the weight of the microcapsule; such a composition providing improved worker exposure characteristics.

Claims (20)

1 . A composition comprising a microcapsule having a polyurea wall encapsulating lambda cyhalothrin and dispersed titanium dioxide particles, wherein the polyurea wall of the microcapsule is made of polyurea polymers derived from a mixture of aromatic polyisocyanate (A) and aromatic diisocyanate (B), provided that the d50 median particle size diameter of the titanium dioxide particles is from 0.15 to 0.5 microns, the d50 median diameter of the microcapsule in the composition is from 1 to 4, microns, the weight ratio of (A) to (B) is about 1:1, the polymer (or wall) content of each microcapsule is from 7 to 8% by weight, the amount of titanium dioxide is present in an amount of from 3.5 to 6% by weight and the amount of lambda cyhalothrin is from 40 to 50% by weight, each based on the weight of the microcapsule; and the amount of the microcapsule in the composition is from 47 to 53% by weight, based on the weight of the composition.

2 . The composition according to claim 1 , in which the aromatic polyisocyanate is polymethylene polyphenylisocyanate.

3 . The composition according to claim 2 , in which the aromatic diisocyanate is toluene diisocyanate.

4 . The composition according to claim 3 , in which the toluene diisocyanate is an isomeric mixture of toluene diisocyanate.

5 . The composition according to claim 1 , wherein the weight ratio of (A) to (B) is 1:1.

6 . The composition according to claim 1 , further comprising thiamethoxam wherein the thiamethoxam is not encapsulated.

7 . The composition according to claim 6 , further comprising lufenuron wherein the lufenuron is not encapsulated.

8 . A composition having an organic phase and an aqueous phase, comprising:

a polyurea polymer microcapsule encapsulating lambda-cyhalothrin;

wherein the lambda-cyhalothrin is about 22.8% w/w;

wherein the polyurea polymer of the microcapsule is about 3.8% w/w formed from isocyanate monomers, wherein the isocyanate monomers are a mixture of aromatic polyisocyanate (A) and aromatic diisocyanate (B) and the weight ratio of (A) to (B) is about 1:1;

wherein the d50 diameter of the microcapsules is about 1.5-3.5 microns;

wherein the organic phase of the composition is about 49.7% w/w; and

wherein the aqueous phase of the composition is about 50.3% w/w.

9 . The composition according to claim 8 , in which the aromatic polyisocyanate is polymethylene polyphenylisocyanate.

10 . The composition according to claim 9 , in which the aromatic diisocyanate is toluene diisocyanate.

11 . The composition according to claim 10 , in which the toluene diisocyanate is an isomeric mixture of toluene diisocyanate.

12 . The composition according to claim 8 , wherein the weight ratio of (A) to (B) is 1:1.

13 . A composition prepared by the steps, comprising: combining the composition of claim 8 with thiamethoxam, wherein the thiamethoxam is present in the composition at about 12.6% w/w of the composition.

14 . A composition prepared by the steps, comprising: combining the composition of claim 8 with thiamethoxam and lufenuron, wherein the thiamethoxam is present in the composition at about 13.2% w/w of the composition and the lufenuron is present in the composition at about 6.6% w/w of the composition.

Assignments (2)
MERGER Recorded Jul 29, 2024
From: SYNGENTA PARTICIPATIONS AG
To: SYNGENTA CROP PROTECTION AG
Reel/Frame 068114/0282 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2020
From: EDLY, KAL; COTTLE, MATTHEW ROBERT
To: SYNGENTA PARTICIPATIONS AG
Reel/Frame 051462/0894 →
Priority Claims (1)
GB 1611467 · Jun 30, 2016 · national
Continuity (1)
Related Publication 20190350196A1 · Nov 21, 2019
References Cited (28)
US 4285720A · Scher · 1981 [cited by applicant]
US 5837290A · Hasslin · 1998 [cited by applicant]
US 5846554A · Scher · 1998 [cited by examiner]
US 6133197A · Chen et al. · 2000 [cited by applicant]
US 6419942B1 · Lo et al. · 2002 [cited by applicant]
US 6555122B2 · Lo et al. · 2003 [cited by applicant]
US 7229949B2 · Jadhav et al. · 2007 [cited by applicant]
US 8828415B2 · Casaña et al. · 2014 [cited by applicant]
US 9241912B2 · Taranta et al. · 2016 [cited by applicant]
US 20050009834A1 · Itoh · 2005 [cited by examiner]
US 20080254082A1 · Toledano · 2008 [cited by examiner]
US 20130115261A1 · Borzatta · 2013 [cited by applicant]
US 20130210863A1 · Dotan · 2013 [cited by examiner]
CN 101460534A · 2009 [cited by applicant]
CN 103304772A · 2013 [cited by applicant]
CN 109691444A · 2019 [cited by applicant]
JP H06238159A · 1994 [cited by applicant]
KR 19990008105A · 1999 [cited by applicant]
KR 19990022458A · 1999 [cited by applicant]
KR 20070027760A · 2007 [cited by applicant]
KR 20140043326A · 2014 [cited by applicant]
WO 9633611A2 · 1996 [cited by applicant]
WO 9744125A1 · 1997 [cited by applicant]
WO 2589290 · 2013 [cited by applicant]
WO 2015127051A1 · 2015 [cited by applicant]
International Search Report & Written Opinion for PCT/EP2017/065541 mailed on Jul. 19, 2017. [cited by applicant]
IPRP for PCT/EP2017/065541, mailed on Jan. 10, 2019. [cited by applicant]
UKIPO; App. No. GB 1611467.0; Combined Search and Examination Report under Sections 17 & 18(3) dated Dec. 23, 2016. [cited by applicant]